DeepMed Research

Pharming Technologies B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: rhC1INH or pdC1INH

First Posted Date: 2011-07-20

Last Posted Date: 2025-04-08

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 181

Registration Number: NCT01397864

Locations: 🇧🇬
UMHAT Alexandrovska EAD, Sofia, Bulgaria
🇭🇷
KBC Split, Split, Croatia
🇭🇷
CHC Sestre milosrdnice, Zagreb, Croatia

and more 14 locations

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Phase 2

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: rhC1INH

First Posted Date: 2011-05-25

Last Posted Date: 2024-03-29

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 57

Registration Number: NCT01359969

Locations: 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇷🇴
Mures County Clinical Hospital, Targu Mures, Romania
🇮🇱
Bnei Zion Hospital, Haifa, Israel

and more 12 locations

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Phase 3

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: Placebo (Saline)
Drug: rhC1INH

First Posted Date: 2010-08-25

Last Posted Date: 2015-08-07

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 75

Registration Number: NCT01188564

Locations: 🇺🇸
Family Allergy and Asthma Center, Atlanta, Georgia, United States
🇺🇸
Allergy, Asthma & Immunology, Assoc, Ltd., Scottsdale, Arizona, United States
🇺🇸
Allergy and Asthma Institute of the Valley, Granada Hills, California, United States

and more 24 locations

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Phase 2

Withdrawn

Conditions: Graft Rejection
Kidney Transplantation

Interventions: Procedure: plasmapheresis and IVIG
Drug: recombinant C1 inhibitor

First Posted Date: 2009-12-18

Last Posted Date: 2012-02-17

Lead Sponsor: Pharming Technologies B.V.

Registration Number: NCT01035593

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

Phase 2

Completed

Conditions: Genetic Disorders
Hereditary Angioedema

Interventions: Drug: Recombinant Human C1 Inhibitor

First Posted Date: 2009-02-26

Last Posted Date: 2018-06-26

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 25

Registration Number: NCT00851409

Locations: 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Târgu-Mureş, Romania
🇳🇱
For information on sites, please contact Pharming Technologies, Leiden, Netherlands

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema
Angioneurotic Edema
Genetic Disorders

Interventions: Drug: Placebo
Drug: recombinant human C1 inhibitor

First Posted Date: 2005-12-06

Last Posted Date: 2012-10-02

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 75

Registration Number: NCT00262301

Locations: 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Tirgu Mures, Romania
🇳🇱
For information on sites, please contact Pharming Medical Affairs Deparment, Leiden, Netherlands

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Phase 2

Completed

Conditions: Genetic Disorders

Interventions: Drug: i.v. recombinant human C1 inhibitor

First Posted Date: 2005-12-06

Last Posted Date: 2013-02-22

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 14

Registration Number: NCT00262288

Locations: 🇳🇱
For information on sites in Europe, please contact Pharming Technologies., Leiden, Netherlands

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Phase 2

Completed

Conditions: Genetic Disorders

Interventions: Drug: i.v. recombinant human C1 inhibitor

First Posted Date: 2005-12-02

Last Posted Date: 2013-04-25

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 14

Registration Number: NCT00261053

Locations: 🇳🇱
For information contact Sonja Visscher, Leiden, Netherlands

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Phase 2

Completed

Conditions: Hereditary Angioedema
Angioneurotic Edema

Interventions: Drug: Recombinant Human C1 Inhibitor
Drug: placebo

First Posted Date: 2005-09-23

Last Posted Date: 2013-02-22

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 77

Registration Number: NCT00225147

Locations: 🇳🇱
For information on sites please contact Pharming Medical Affairs Department, Leiden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy